NSE filing, NSE: BALAXI. Summary written from the filing by ALFA Finder's alert engine.
Balaxi Pharmaceuticals Ltd: key numbers
- Share price
- ₹19.15
- Market cap
- ₹105.7 Cr
- Revenue (annual)
- ₹270.2 Cr
- Net profit (annual)
- ₹1.42 Cr
- P/E (TTM)
- 43.6×Sector 45.9×
- Promoter holding
- 65.99%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Balaxi Pharmaceuticals Ltd
All →Balaxi Pharmaceuticals Board Meeting Date
Balaxi Pharmaceuticals will meet on 12 November 2026 to approve unaudited half-year results. The trading window stays closed until 14 November 2026.
Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals Limited reported nil activity regarding the re-lodgement of physical share transfer requests for the period ended September 2026.
Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals reported nil activity regarding the re-lodgement of physical share transfer requests for August 2026. This is a routine regulatory compliance filing.
Balaxi Pharmaceuticals Business Update
Balaxi Pharmaceuticals has received WHO-GMP certification for its first pharmaceutical formulation manufacturing facility in Telangana. The facility has commenced manufacturing initially approved products for international markets.
Balaxi Pharmaceuticals Annual General Meeting
Balaxi Pharmaceuticals Limited held its 83rd Annual General Meeting on August 24, 2026. Shareholders voted on financial statements and director re-appointments during the proceedings.
Balaxi Pharmaceuticals Investor Presentation: Key Takeaways
Balaxi reported 14.1% YoY revenue growth in Q1 FY27, driven by market diversification and its first proprietary manufacturing facility. Strategy emphasizes backward integration in Latin America and Africa.
Other management change announcements
All →Himadri Speciality Chemical Management Change
Himadri Speciality Chemical's board revised its senior management list following organisational restructuring. Six personnel are listed, including the CFO and Company Secretary.
HMT Management Change
HMT Ltd intimated the resignation of Aparna R, Assistant General Manager (F&A), who ceases as CFO and KMP effective close of business on October 30, 2026. Her resignation letter is attached.
Share India Securities Management Change
Share India Securities appointed Krishan Singh Barguzar as Non-Executive Independent Director for 36 months, effective 30 October 2026. He is a former SBI Chief General Manager.
Indian Renewable Energy Development Agency Management Change
IREDA appointed Jatin Kumar Nayak as CMD effective October 30, 2026. Dr. Bijay Kumar Mohanty ceased to hold the additional CMD charge that day.
Kwality Wall's (India) Management Change
Kwality Wall's appointed Tahir Toloy Tanridagli as MD and CEO for three years from November 1, 2026. Vivek Sarbhai ceases as Senior Management Personnel from October 31.
- Execution
- 3 years (1 November 2026 to 31 October 2029)
Power Grid Corporation of India Management Change
Power Grid named Pankaj Pandey Director (Operations) on a Ministry of Power order, effective on or after 1 December 2026. He retires on 30 June 2030.